These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6743770)

  • 1. [Morphometric study of hepatic peroxisomes in hyperlipoproteinemic patients treated with fenofibrate].
    Gariot P; Pointel JP; Barrat E; Drouin P; Debry G
    Biomed Pharmacother; 1984; 38(2):101-6. PubMed ID: 6743770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate and human liver. Lack of proliferation of peroxisomes.
    Gariot P; Barrat E; Mejean L; Pointel JP; Drouin P; Debry G
    Arch Toxicol; 1983 Jun; 53(2):151-63. PubMed ID: 6882216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fenofibrate: animal toxicology in relation to side-effects in man (author's transl)].
    Blane GF; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3737-46. PubMed ID: 7208340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fenofibrate, efficacy and tolerance in long-term treatment (author's transl)].
    Fromantin M; Gautier D; Quatre JM; Bon R
    Therapie; 1981; 36(4):473-6. PubMed ID: 7292431
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
    Hong XZ; Li LD; Wu LM
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
    Barnard SD; Molello JA; Caldwell WJ; Lebeau JE
    Nouv Presse Med; 1980 Oct; 9(40):3005-7. PubMed ID: 7443440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphometric study of human hepatic cell modifications induced by fenofibrate.
    Gariot P; Barrat E; Drouin P; Genton P; Pointel JP; Foliguet B; Kolopp M; Debry G
    Metabolism; 1987 Mar; 36(3):203-10. PubMed ID: 3821501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias.
    Harvengt C; Heller F; Desager JP
    Artery; 1980; 7(1):73-82. PubMed ID: 7247733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of fenofibrate on the lipid level in diabetic patients].
    Häring HU; Schleicher E; Renner R; Mehnert H
    MMW Munch Med Wochenschr; 1983 Sep; 125(35):751-3. PubMed ID: 6415427
    [No Abstract]   [Full Text] [Related]  

  • 11. [Muscular toxicity due to fenofibrate. Apropos of a case].
    Giraud P; Cassou M; Paul R; Guidet M
    Rev Rhum Mal Osteoartic; 1982 Feb; 49(2):162. PubMed ID: 7063798
    [No Abstract]   [Full Text] [Related]  

  • 12. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate prevents orotic acid--induced hepatic steatosis in rats.
    Ferreira AV; Parreira GG; Porto LC; Mario EG; Delpuerto HL; Martins AS; Botion LM
    Life Sci; 2008 Apr; 82(15-16):876-83. PubMed ID: 18374364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic].
    Ceska R; Stulc T
    Cas Lek Cesk; 2000 Jun; 139(12):369-73. PubMed ID: 10953407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferation and beta-oxidation in Fao and MH1C1 rat hepatoma cells, HepG2 human hepatoblastoma cells and cultured human hepatocytes: effect of ciprofibrate.
    Duclos S; Bride J; Ramirez LC; Bournot P
    Eur J Cell Biol; 1997 Apr; 72(4):314-23. PubMed ID: 9127731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
    Hottelart C; el Esper N; Achard JM; Pruna A; Fournier A
    Nephrologie; 1999; 20(1):41-4. PubMed ID: 10081035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients.
    Blümcke S; Schwartzkopff W; Lobeck H; Edmondson NA; Prentice DE; Blane GF
    Atherosclerosis; 1983 Jan; 46(1):105-16. PubMed ID: 6838687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
    Levin A; Duncan L; Djurdjev O; Shapiro RJ; Frohlich J; Belanger A; Dumas R; Ross S
    Clin Nephrol; 2000 Feb; 53(2):140-6. PubMed ID: 10711416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats].
    Yan M; Meng FL; Lu RJ; Jia XQ; Zhao XC
    Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):86-9. PubMed ID: 12648401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.